Walleye Capital
KYTX icon

Walleye Capital’s Kyverna Therapeutics KYTX Stock Holding History

Walleye Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$330K Buy
+38,196
New +$318K ﹤0.01% 2996
2024
Q3 		– Sell
-156,515
Closed -$1.17M – 5959
2024
Q2 		$1.17M Buy
156,515
+6,515
+4% +$99.5K ﹤0.01% 2669
2024
Q1 		$3.73M Buy
+150,000
New +$4.19M 0.01% 1525

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Walleye Capital's KYTX Position: Q1 2026 in Review

Walleye Capital opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 38,196 shares worth $330K. The stake represents ﹤0.01% of the portfolio and ranks #2996 among its holdings. This is a return to the name: Walleye Capital previously reported a position in KYTX as recently as Q2 2024.

Walleye Capital first reported a position in KYTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $3.73M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Walleye Capital held 38,196 shares of Kyverna Therapeutics worth $330K as of Q1 2026.
  • Kyverna Therapeutics was a new Walleye Capital position in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2996 holding.
  • Walleye Capital first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Walleye Capital's Kyverna Therapeutics position peaked at $3.73M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.